Exhibit 10.1
 
AMENDMENT TO
SENIOR SECURED CONVERTIBLE PROMISSORY NOTES

         This Amendment is made as of the 26th day of October 2009, by and
between Urigen Pharmaceuticals, Inc. a Delaware corporation with its principal
place of business at 27 Maiden Lane, Suite 595, San Francisco, California 94108
(the “Company”) and Platinum-Montaur Life Sciences, LLC (the “Lender”) a
Delaware limited liability company.

WHEREAS, the parties have entered into a Note Purchase Agreement dated as of
January 9, 2009 (the “Purchase Agreement”), as amended by Amendment to
Transaction Documents dated as of April 22, 2009 and further amended by Second
Amendment to Transaction Documents dated as of August 13, 2009 pursuant  to
which the Company issued to the Lender (collectively the “Notes”): (A) Senior
Secured Convertible Promissory Note No. 1 dated January 9, 2009  in the
principal amount of $257,000; (B)  Senior Secured Convertible Promissory Note
No. 2 dated April 22, 2009 in the principal amount of $40,000; (C) Senior
Secured Convertible Promissory Note No. 3 dated August 13, 2009  in the
principal amount of $202,500.

WHEREAS, pursuant to their terms, the Notes matured on October 9, 2009.

WHEREAS, the parties wish to amend the Note to extend the maturity date to April
9, 2010;

NOW, THEREFORE, for and in consideration of the foregoing recitals, and other
good and valuable consideration, the receipt and legal sufficiency of which are
hereby acknowledged, the parties agree as follows:
 
 
 
 

--------------------------------------------------------------------------------

 
 

1.           The maturity date of each of the Notes is extended to provide that
the outstanding balance of each of the Notes shall be due and payable by the
Company on April 9, 2010.

2.           The provisions of the Notes, as modified herein, shall remain in
full force and effect in accordance with their terms and are hereby ratified and
confirmed.  The Lender does not in any way waive the Company’s obligations to
comply with any of the provisions, covenants and terms of the Notes, nor does
the Lender waive any other right the Lender may have at law or in equity.
 
3.           This Amendment shall be governed by the laws of the State of New
York, without regards to the conflict of law provisions thereof.
 

 
[Remainder of page intentionally left blank.]
 
 
 
 

--------------------------------------------------------------------------------

 
 

IN WITNESS WHEREOF, the undersigned have caused this Amendment to the Notes  to
be executed as of the date first above written.
 

URIGEN PHARMACEUTICALS, INC.

By:__/s/ Martin E. Shmagin_________________
Name:  Martin E. Shmagin
Title:    Chief Financial Officer

PLATINUM-MONTAUR LIFE SCIENCES, LLC

.
By:__/s/ Michael Goldberg___________________
Name:  Michael Goldberg
Title:  Portfolio Manager